GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Dignitana AB (OTCPK:DIZTF) » Definitions » EV-to-EBITDA

Dignitana AB (Dignitana AB) EV-to-EBITDA : -506.63 (As of May. 26, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Dignitana AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Dignitana AB's enterprise value is $16.21 Mil. Dignitana AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.03 Mil. Therefore, Dignitana AB's EV-to-EBITDA for today is -506.63.

The historical rank and industry rank for Dignitana AB's EV-to-EBITDA or its related term are showing as below:

DIZTF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -588.28   Med: -16.72   Max: -1.41
Current: -486.87

During the past 13 years, the highest EV-to-EBITDA of Dignitana AB was -1.41. The lowest was -588.28. And the median was -16.72.

DIZTF's EV-to-EBITDA is ranked worse than
100% of 488 companies
in the Medical Devices & Instruments industry
Industry Median: 16.205 vs DIZTF: -486.87

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-26), Dignitana AB's stock price is $0.15. Dignitana AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.026. Therefore, Dignitana AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Dignitana AB EV-to-EBITDA Historical Data

The historical data trend for Dignitana AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dignitana AB EV-to-EBITDA Chart

Dignitana AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.27 -15.95 -20.10 -56.17 -631.48

Dignitana AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.17 -93.59 -37.92 -27.48 -631.48

Competitive Comparison of Dignitana AB's EV-to-EBITDA

For the Medical Devices subindustry, Dignitana AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dignitana AB's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Dignitana AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Dignitana AB's EV-to-EBITDA falls into.



Dignitana AB EV-to-EBITDA Calculation

Dignitana AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=16.212/-0.032
=-506.63

Dignitana AB's current Enterprise Value is $16.21 Mil.
Dignitana AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dignitana AB  (OTCPK:DIZTF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Dignitana AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.15/-0.026
=At Loss

Dignitana AB's share price for today is $0.15.
Dignitana AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.026.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Dignitana AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Dignitana AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Dignitana AB (Dignitana AB) Business Description

Traded in Other Exchanges
Address
Traktorgranden 3, Lund, SWE, 226 60
Dignitana AB is a medical technology company, that develops, produces, and markets The DigniCap Scalp Cooling System. It is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. Geographically, it derives a majority of revenue from the USA.